Trial: 201902041

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Phase

III

Principal Investigator

Bartlett, Nancy

Disease Site

Chronic Lymphocytic Leukemia (CLL); Lymphoid Leukemia

Learn more about this study at: clinicaltrials.gov